IABP-SHOCK II Trial - Kardio.hr

More documents

Recommendations

Info

Disclosures Funding: German Research Foundation German Heart Research Foundation German Cardiac Society Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte University of Leipzig – Heart Center Unrestricted grant by: Maquet Cardiopulmonary AG, Hirrlingen, Germany Teleflex Medical, Everett, MA, USA Potential Conflict of Interest: Research Funding: Terumo, Lilly, Maquet Cardiovascular, Teleflex Medical Consulting: Maquet Cardiovascular, Lilly Speaker Honoraria: Lilly, Astra Zeneca, Daiichi Sankyo, Boehringer Ingelheim, Maquet Cardiovascular, Medicines Company
Background IABP in Cardiogenic Shock History: 1962 Animal studies Moulopoulos et al. Am Heart J 1962;63:669-675 1968 First clinical description in shock Kantrowitz et al. JAMA 1968;203:135-140 1973 Hemodynamic effects in shock, Mortality unchanged Scheidt et al. NEJM 1973;288:979-984 > 40 years > 1 Million patients treated, low complication rate, Benchmark registry Ferguson et al. JACC 2001;38:1456-1462
Page 1: Randomized comparison of intraaorti
Page 5 and 6: Background Mortality IABP vs no IAB
Page 7 and 8: Methods Study Sites and Organisatio
Page 9 and 10: Methods Statistical Methodology Sam
Page 11 and 12: Results Age (years); median (IQR) M
Page 13 and 14: Results Simplified Acute Physiology
Page 15 and 16: Results Serum Lactate (mmol/l) 9 8
Page 17 and 18: Results Primary Study Endpoint (30-
Page 19 and 20: Results Safety IABP (n=300) Control
Page 21 and 22: Summary + Conclusions • IABP supp
Page 23: www.nejm.org

IABP-SHOCK II Trial - Kardio.hr

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?